Recent Updates
Recently added Catalysts
VKTX

Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture

Wednesday, July 12, 2017 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
13.6%
average across 5 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
VK2735
Phase 3 · Weight Loss

Full Press Release Details

Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture.
ShareAdd on Google
Tags: VKTX Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jul 12, 2017

Biotech snapshot

Cash runway
$502M liquidity · $42M/mo burn
~11 mo
Medium dilution risk
Lead asset
VK2735Phase 3
Weight Loss →

Catalyst track record

+53%
best trade around VKTX's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for VKTX.

See every catalyst's timing & PoA →